Stock ATNM ACTINIUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
6.87 USD +4.73% Intraday chart for Actinium Pharmaceuticals, Inc. +0.29% +35.24%
Apr. 26 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 18 Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting CI

Evolution of the average Target Price on Actinium Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

79c218a94bd37137a9.sav1X9TIaJPtINJ3UZ_J7cCgklcCSULIWxxrYyMEwfE.xvjYG5i8MvSCV5UHFMb4l7ja6Bl4PiGuN1hSNkUyrISEwJtmn6MGq4Nm5g~27e008f651cf50be9156dfc29bcaa208

Analyst Recommendations on Actinium Pharmaceuticals, Inc.

Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating MT
B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating MT
HSBC Starts Actinium Pharmaceuticals With Buy Rating, Price Target is $11.60 MT
HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $50 From $53, Keeps Buy Rating MT
B. Riley Raises Actinium Pharmaceuticals' Price Target to $20 From $18, Keeps Buy Rating MT
William Blair Downgrades Actinium Pharmaceuticals to Market Perform Rating From Outperform MT
HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $53 From $45, Maintains Buy Rating MT
B. Riley Raises Actinium Pharmaceuticals' PT to $18 From $16 After Positive Update of Phase 3 SIERRA Trial for Iomab-B, Keeps Buy Rating MT
Cantor Fitzgerald Initiates Actinium Pharmaceuticals at Overweight with $20 Price Target MT
B. Riley Securities Initiates Actinium Pharmaceuticals at Buy with $16 Price Target, Says Market Potential for Iomab-B Conditioning Underappreciated MT
Alliance Global Adjusts Price Target on Actinium Pharmaceuticals to $25 From $20, Maintains Buy Rating MT
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML CI
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $45 From $57, Maintains Buy Rating MT
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating MT
Actinium Pharmaceuticals, Inc. Reports 67% Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH CI
ACTINIUM PHARMACEUTICALS : Alliance Global Starts Actinium Pharmaceuticals at Buy With $25 Price Target MT
Actinium Pharmaceuticals : Reports 100% Remission Rate in Cohort of Phase 1 Study of Actimab-A CLAG; Shares Rise 10% MT
Actinium Pharmaceuticals, Inc. Announces 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML CI
Actinium Pharmaceuticals, Inc. Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.87 USD
Average target price
25.47 USD
Spread / Average Target
+270.69%
High Price Target
50 USD
Spread / Highest target
+627.80%
Low Price Target
9.8 USD
Spread / Lowest Target
+42.65%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Actinium Pharmaceuticals, Inc.

Maxim
B. Riley
HSBC
HC Wainwright
William Blair & Co.
Cantor Fitzgerald
Alliance Global Partners

Ratings for Actinium Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ATNM Stock
  4. Consensus Actinium Pharmaceuticals, Inc.